Investigating the mechanisms of HER2+breast cancer cell redirection

被引：0
|
作者：
Campbell, Caroline J. [1 ]
Booth, Brian W. [1 ]
机构：
[1] Clemson Univ, Clemson, SC USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2536
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Investigating the immune profile of early stage HER2+breast cancer patients receiving chemotherapy and HER2-targeted therapies
    Collins, Denis M.
    Gaynor, Nicola
    Madden, Stephen
    Toomey, Sinead
    Qiu, Ji
    Blayney, Jaine
    Blanco, Alfonso
    Fletcher, Jean
    Moran, Barry
    Kaukonen, Damien
    Ramirez, Javier Sanchez
    Kay, Elaine
    O'Connor, Darran
    Teiserskiene, Ausra
    Eustace, Alex
    Kennedy, Richard
    LaBaer, Joshua
    Gallagher, William
    Hennessy, Bryan
    Crown, John
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 487 - 487
  • [22] Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+Breast Cancer Subtypes
    Watson, Spencer S.
    Dane, Mark
    Chin, Koei
    Tatarova, Zuzana
    Liu, Moqing
    Liby, Tiera
    Thompson, Wallace
    Smith, Rebecca
    Nederlof, Michel
    Bucher, Elmar
    Kilburn, David
    Whitman, Matthew
    Sudar, Damir
    Mills, Gordon B.
    Heiser, Laura M.
    Jonas, Oliver
    Gray, Joe W.
    Korkola, James E.
    CELL SYSTEMS, 2018, 6 (03) : 329 - +
  • [23] Targeting glucose metabolism in HER2+breast cancer.
    Chang, Simone
    Chesney, Jason
    Trent, John O.
    Telang, Sucheta
    CANCER RESEARCH, 2021, 81 (13)
  • [24] A predictor of response in HER2+breast cancer-at last!
    Badve, Sunil S.
    Gokmen-Polar, Yesim
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022,
  • [25] Safety of trastuzumab in women with HER2+breast cancer.
    Nowsheen, Somaira
    Aziz, Khaled
    Park, Jae Yoon
    Villarraga, Hector R.
    Herrmann, Joerg
    Ruddy, Kathryn Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Key Genes and Prognostic Analysis in HER2+Breast Cancer
    Weng, Yujie
    Liang, Wei
    Ji, Yucheng
    Li, Zhongxian
    Jia, Rong
    Liang, Ying
    Ning, Pengfei
    Xu, Yingqi
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [27] Estimating costs of relapsing HER2+breast cancer in Spain
    Colomer, R.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Albanell, J.
    CANCER RESEARCH, 2017, 77
  • [28] TRASTUZUMAB INDUCED CARDIOTOXICITY IN PATIENTS WITH HER2+BREAST CANCER
    Santamaria Elena, Capilla
    Garcia Beatriz, Benitez
    Jose Antonio, Romero Garrido
    Aunon Pilar, Zamora
    Abad Gema, Casado
    del Valle Luis, Gonzalez
    Ambrosio Alicia, Herrero
    ATENCION FARMACEUTICA, 2013, 15 (04): : 261 - 267
  • [29] Assessing Neurohormonal in HER2+Breast Cancer Patients With CTRCD
    Albulushi, Arif
    Al-Farhan, Hatem
    JACC: CARDIOONCOLOGY, 2024, 6 (04): : 625 - 626
  • [30] COSTS OF RECURRENCE IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Albanell, J.
    Colomer, R.
    Martin, M.
    Martinez, D.
    Arroyo, I
    Moreno, E.
    VALUE IN HEALTH, 2020, 23 : S435 - S435
12345